Marinus Pharmaceuticals traded at $4.76 this Friday July 1st, decreasing $0.08 or 1.65 percent since the previous trading session. Looking back, over the last four weeks, Marinus Pharmaceuticals lost 8.81 percent. Over the last 12 months, its price fell by 74.73 percent. Looking ahead, we forecast Marinus Pharmaceuticals to be priced at 4.86 by the end of this quarter and at 4.47 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4.76
Daily Change
-1.65%
Yearly
-74.73%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,691.00 -34.00 -0.59% -47.57%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
ALKERMES 30.53 0.74 2.48% 20.67%
Amgen 245.55 2.25 0.92% -1.27%
Aptinyx Inc 0.55 -0.01 -1.42% -80.50%
Biogen 210.63 6.69 3.28% -39.60%
Enanta Pharmaceuticals 49.63 2.36 4.99% 12.29%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Intra Cellular Therapies 55.17 -1.91 -3.35% 30.58%
Marinus Pharmaceuticals 4.76 -0.08 -1.65% -74.73%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Minerva Neurosciences 3.59 0.28 8.46% 54.74%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Supernus Pharmaceuticals 29.35 0.43 1.49% -3.36%
UCB 82.60 1.96 2.43% -8.22%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%

Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.